DOI: https://doi.org/10.25251/skin.1.supp

Published: 2017-10-27

Atopic Dermatitis

Can the Skin Microbiota of Patients Suffering from Atopic Dermatitis be Modified after Balneotherapy?

S Seite, D Moyal
| DOI https://doi.org/10.25251/skin.1.supp.33

Page s34

Poster PDF

Comparison of an Anhydrous OTC Balm Containing 15% Zinc Oxide, 2% Colloidal Oatmeal, and 1% Allantoin Versus 1% Hydrocortisone Cream in Subjects with Mild-to-Moderate Dermatitis

A Donald, M Babcock
| DOI https://doi.org/10.25251/skin.1.supp.34

Page s35

Poster PDF

Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis

Eric Simpson, Andrew Bushmakin, Joseph C Cappelleri, Thomas Luger, Sonja Stander, Wynnis Tom, William C Ports, Anna M Tallman, Huaming Tan, Robert A Gerber
| DOI https://doi.org/10.25251/skin.1.supp.35

Page s36

Poster PDF

Dupilumab with Concomitant Topical Corticosteroids in Atopic Dermatitis Patients who are Inadequately Controlled with or Medically Inadvisable for Cyclosporine A: a Phase 3 Clinical Trial (LIBERTY AD CAFE)

Marjolein de Bruin-Weller, Diamant Thaci, Catherine Smith, Allen Radin, Rick Zhang, Bolanle Akinlade, Abhijit Gadkari, Laurent Eckert, Thomas Hultsch, Gianluca Pirozzi, Neil MH Graham, Brad Shumel
| DOI https://doi.org/10.25251/skin.1.supp.36

Page s37

Poster PDF

Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2)

Carlos Ferrandiz, Pablo de la Cueva Dobao, Eric L Simpson, Rick Zhang, Abjijit Gadkari, Laurent Eckert, Bolanle Akinlade, Marius Ardeleanu
| DOI https://doi.org/10.25251/skin.1.supp.37

Page s38

Poster PDF

The Effect of Crisaborole Ointment, 2%, on Pruritus in Patients with Atopic Dermatitis: An Extended Analysis

Gil Yosipovitch, Eric Simpson, Huaming Tan, Robert A Gerber, Thomas Luger, Sonja Stander, Wynnis Tom, Joseph C Cappelleri, Andrew G Bushmakin, William C Ports, Anna M Tallman
| DOI https://doi.org/10.25251/skin.1.supp.38

Page s39

Poster PDF

An Investigator Blinded Randomized Study Evaluating HOCl in the Treatment of Atopic Dermatitis-Associated Pruritus

Brian Berman, Mark Nestor
| DOI https://doi.org/10.25251/skin.1.supp.39

Page s40

Poster PDF

A Moisturizing Spray Ointment to Help Alleviate Dry Skin Symptoms Associated with Atopic Eczema, Psoriasis, and Xerosis

T M Weber, C E Arrowitz, U Scherdin, A M Schoelermann, A Filbry
| DOI https://doi.org/10.25251/skin.1.supp.40

Page s41

Poster PDF

Observational Study on Patients with Atopic Dermatitis

S Seite, D Moyal
| DOI https://doi.org/10.25251/skin.1.supp.41

Page s42

Poster PDF

Topical Treatment Utilization for Patients with Atopic Dermatitis in the United States and Budget Impact Analysis of Crisaborole Ointment, 2%

Ryan Clark, Duygu Bozkaya, Mark Levenberg, Steven Faulkner, Timothy W Smith, Robert A Gerber
| DOI https://doi.org/10.25251/skin.1.supp.42

Page s43

Poster PDF

Using a Specific Cleanser for Patients with Mild Atopic Dermatitis: Relationship Between Cinical Efficacy and Skin Microbiota Modification

S Seite, D Moyal
| DOI https://doi.org/10.25251/skin.1.supp.43

Page s44

Poster PDF

Validation of the Severity of Pruritus Scale for the Assessment of Pruritus in Atopic Dermatitis

Gil Yosipovitch, Eric Simpson, Andrew G Bushmakin, Joseph C Cappelleri, Thomas Luger, Sonja Stander, Wynnis Tom, Katy Benjamin, William C Ports, Anna M Tallman
| DOI https://doi.org/10.25251/skin.1.supp.44

Page s45

Poster PDF

Acne & Rosacea

DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application

Srinivas Sidgiddi, Usha Ranganathan, Anirudh Gautam
| DOI https://doi.org/10.25251/skin.1.supp.45

Page s46

Poster PDF

Effect of Air Pollution on Sebum Rate and Acne: How to Manage Acneic Skin in a Polluted Environment

D Moyal, S Seite
| DOI https://doi.org/10.25251/skin.1.supp.46

Page s47

Poster PDF

Efficacy and Saftey of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Subjects with Severe Inflammatory Acne (Non-Nodulocystic) that are Candidates for Oral Isotretinoin

James Del Rosso, Linda Stein Gold, Sandra Marchese Johnson, Maria Jose Rueda, Hilary Baldwin, Edward L Lain, Megan Landis, Marta Rendon, Emil Tanghetti, Jonathan Weiss
| DOI https://doi.org/10.25251/skin.1.supp.47

Page s48

Poster PDF

The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Phase 2 and Phase 3 Studies

Linda Stein Gold, Sunil Dhawan, Jonathan Weiss, Zoe D Draelos, Herman Ellman
| DOI https://doi.org/10.25251/skin.1.supp.48

Page s49

Poster PDF

Efficacy and Tolerability of Tazarotene Foam 0.1% Across Age, Gender, and Race: An Integrated Review of Two Phase III Trials

Rhonda Schreiber, Kaytiana Crane, Juhin Patel
| DOI https://doi.org/10.25251/skin.1.supp.49

Page s50

Poster PDF

Observational Study on Patients with Acne and at Risk of Post-Inflammatory Hyperpigmented Lesions

S Seite, D Moyal
| DOI https://doi.org/10.25251/skin.1.supp.50

Page s51

Poster PDF

Pharmacokinetic Evaluation of Once-Daily Topical 4% Minocycline Foam in Adult and Pediatric Subjects with Moderate-to-Severe Acne in Two Phase 1 Studies

Terry M Jones, Herman Ellman, Tina deVries
| DOI https://doi.org/10.25251/skin.1.supp.51

Page s52

Poster PDF

Rapid Improvement with BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris: a Randomized, Double-Blind, Vehicle-Controlled Study

Andrew Alexis, James Del Rosso, Seemal R Desai, Jeanine Downie, Zoe D Draelos, Christina Feser, Rion Forconi, Joseph Fowler, Michael Gold, Joely Kaufman-Janette, Edward Lain, Mark Lee, Mark Ling, Ava Shamban, William Werschler, AnnaMarie Daniels
| DOI https://doi.org/10.25251/skin.1.supp.52

Page s53

Poster PDF

Skin Microbiome and Acne Vulgaris: Staphylococcus, a New Actor in Acne

B Dreno, R Martin, A Khammari, D Moyal, J B Henley, S Seite
| DOI https://doi.org/10.25251/skin.1.supp.53

Page s54

Poster PDF

Topical Green Tea Polyphenols and Caffeine as a Treatment for Acne Vulgaris

Sarah Y Siu, Georgina M Ferzli, Neil Brody
| DOI https://doi.org/10.25251/skin.1.supp.54

Page s55

Poster PDF

The Use of Lipohydroxy Acid in Skin Care and Acne Treatment

Joshua A Zeichner
| DOI https://doi.org/10.25251/skin.1.supp.55

Page s56

Poster PDF

Visualization of Cutaneous Distribution of Minocycline of a Topical Gel in Human Facial Skin with Two-Photon Excited Fluorescence Lifetime Imaging Microscopy (FLIM) and Phasor Analysis

Sinyoung Jeong, Maiko Hermsmeier, Sam Osseiran, Akira Yamamoto, Usha Nagavarapu, Kin F Chan, Conor L Evans
| DOI https://doi.org/10.25251/skin.1.supp.56

Page s57

Poster PDF

Disorders of Pigmentation

Clinical Efficacy and Tolerability of a Topical HQ-Free Serum on Females with self-Reported Pregnancy-Induced Facial Melasma

Elizabeth T Makino, Priscilla Tan, Rahul C Mehta
| DOI https://doi.org/10.25251/skin.1.supp.99

Page s100

Poster PDF

Combining In-Office Chemical Peel Procedures with Topical Therapy of a Comprehensive Pigmentation Control Product for Multi-Ethnic Subjects with Moderate-to-Severe Facial Hyperpigmentation

Katie H Schneider, Lisa T Goberdhan, Elizabeth T Makino, Rahul C Mehta
| DOI https://doi.org/10.25251/skin.1.supp.100

Page s101

Poster PDF

Ozenoxacin, a Novel, Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients with Impetigo: Phase III Clinical Trials Pooled Analysis Results

Nuria Albareda, Noah Rosenberg, Sandra Roth, Ilonka Zsolt, Theodore Rosen, Adelaide A Hebert
| DOI https://doi.org/10.25251/skin.1.supp.101

Page s102

Poster PDF

A Randomized Vehicle-Controlled Trial to Assess the Efficacy, Safety, and Tolerability of Ozenoxacin 1% Cream in 412 Patients 2 Months and Older with Impetigo

N Albareda, J Zeichner, N Rosenberg
| DOI https://doi.org/10.25251/skin.1.supp.102

Page s103

Poster PDF

A Randomized Vehicle-Controlled Trial to Assess the Efficacy, Safety, and Tolerability of Ozenoxacin 1% Cream in 465 Patients 2 Years and Older with Impetigo

N Albareda, J Zeichner
| DOI https://doi.org/10.25251/skin.1.supp.103

Page s104

Poster PDF

Hyperhidrosis

Burden of Axillary Hyperhidrosis Using a Patient-Reported Outcome Measure to Assess Impact on Activities and Bothersomeness

David M Pariser, Adelaide A Hebert, Janice Drew, John Quiring, Dee Anna Glaser
| DOI https://doi.org/10.25251/skin.1.supp.92

Page s93

Poster PDF

Confirmatory Psychometric Evaluation of the Axillary Sweating Daily Diary: A Vaildated Patient-Reported Outcome Measure to Assess Axillary Hyperhidrosis Sweating Severity

Dee Anna Glaser, Adelaide A Hebert, Sheri Fehnel, Dana DiBenedetti, Lauren Nelson, Janice Drew, David M Pariser
| DOI https://doi.org/10.25251/skin.1.supp.93

Page s94

Poster PDF

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

Dee Anna Glaser, Adelaide A Hebert, Alexander Nast, William P Werschler, Stephen Shideler, Lawrence Green, Richard D Mamelok, Janice Drew, John Quiring, David M Pariser
| DOI https://doi.org/10.25251/skin.1.supp.94

Page s95

Poster PDF

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

David M Pariser, Adelaide A Hebert, Janice Drew, John Quiring, Dee Anna Glaser
| DOI https://doi.org/10.25251/skin.1.supp.95

Page s96

Poster PDF

Miscellaneous

Efficacy and Tolerance of a New Non-Steroidal Prescription Cream in the Treatment of Mild Facial Seborrheic Dermatitis

P Valderas-Martinez, A Garre, C Granger
| DOI https://doi.org/10.25251/skin.1.supp.133

Page s134

Poster PDF

Bensal HP (BHP-410), a Novel Antimicrobial Agent with Activity Against MRSA, VRE, Gram-negative MDROs, Yeasts, and Dermatophytic Fungi

K S Thomson, G K Thomson, J Biehle, A Deeb, J Crawford, R Herrera, I Robledo, G Vazquez
| DOI https://doi.org/10.25251/skin.1.supp.134

Page s135

Poster PDF

The Effect of Econazole Nitrate Topical Foam, 1% on Signs and Symptoms (Pruritis) of Interdigital Tinea Pedis

Lauren Hoffman, Isabelle Raymond, Leon Kircik
| DOI https://doi.org/10.25251/skin.1.supp.135

Page s136

Poster PDF

Ex-vivo Determination of Antifungal Activity of a New Prescription Non-Steroidal Facial Cream Against Malassezia furfur in Human Skin Explants

C Granger, F Goni-de-Cerio, G Martinez-Masana, A Garre
| DOI https://doi.org/10.25251/skin.1.supp.136

Page s137

Poster PDF

An Open-Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate Gel 0.05% for the Treatment of Verruca Vulgaris

Neal D Bhatia
| DOI https://doi.org/10.25251/skin.1.supp.137

Page s138

Poster PDF

The Role of Cutaneous Microbiota Harmony in Maintaining a Functional Skin Barrier

H E Baldwin, N C Bhatia, A Friedman, T Prunty, R Martin, S Seite
| DOI https://doi.org/10.25251/skin.1.supp.138

Page s139

Poster PDF

Introduction

Why Publish this Special Issue? A New Paradigm in the Use of Technology to Aid in the Widespread Dissemination of Dermatologic Knowledge

Editorial Team

Page s1

Full Article PDF

SKIN Fall Clinical Dermatology Conference® Poster Supplement Copyright Statement

Editorial Team
Copyright Statement

Psoriasis

A Case Study Series to Evaluate the Safety and Efficacy of a Novel Keratolytic in Patients Diagnosed with Plaque Psoriasis

Tien Q Nguyen, Andrea Nguyen
| DOI https://doi.org/10.25251/skin.1.supp.1

Page s2

Poster PDF

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Vincent Piguet, Andrew Blauvelt, Daniel Burge, Luke Peterson, Janice Drew, Robert Rolleri, Jolanta Weglowska
| DOI https://doi.org/10.25251/skin.1.supp.2

Page s3

Poster PDF

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Diamant Thaci, Alice Gottlieb, Kristian Reich, Jerry Bagel, Daniel Burge, Luke Peterson, Janice Drew, Catherine Arendt, Jolanta Weglowska
| DOI https://doi.org/10.25251/skin.1.supp.3

Page s4

Poster PDF

Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab

Kim A Papp, Andrew Blauvelt, Mary Flack, Yihua Gu, Elizabeth HZ Thompson
| DOI https://doi.org/10.25251/skin.1.supp.4

Page s5

Poster PDF

Cost Per Responder Analysis of Guselkumab versus Adalimumab using Efficacy Results fromm a Head-to-Head Clinical Trial in Patients with Moderate to Severe Plaque Psoriasis

A Teeple, E Muser
| DOI https://doi.org/10.25251/skin.1.supp.5

Page s6

Poster PDF

Defining and Treating Moderate Plaque Psoriasis in a Real-World Clinical Setting: A Dermatologist Survey and Prospective 6-Month Chart Review of Patients Treated with Apremilast

Melissa L F Knuckles, Eugenia Levi, Jennifer Soung
| DOI https://doi.org/10.25251/skin.1.supp.6

Page s7

Poster PDF

DFD-01, a Betamethasone Dipropionate 0.05% Spray, Improved Quality of Life and Treatment Satisfaction in Subjects with Moderate Psoriasis

Joseph Fowler, Kent Allenby, Srinivas Sidgiddi
| DOI https://doi.org/10.25251/skin.1.supp.7

Page s8

Poster PDF

DFD-01, a VCA midpotent beteamethasone dipropionate 0.05% emollient-like spray formulation, demonstrates earlier onset of action compared with a super potent topical steroid for the treatment of moderate psoriasis

Leon Kircik, Jonathan S Weiss, Kent Allenby
| DOI https://doi.org/10.25251/skin.1.supp.8

Page s9

Poster PDF

Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis

Bruce Strober, Kim A Papp, Mary Flack, Yihua Gu, Elizabeth HZ Thompson, Wendell C Valdecantos
| DOI https://doi.org/10.25251/skin.1.supp.9

Page s10

Poster PDF

Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study)

Bruce Strober, Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin
| DOI https://doi.org/10.25251/skin.1.supp.10

Page s11

Poster PDF

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

Andrew Blauvelt, Craig Leonardi, Claus Zachariae, Russel Burge, Terri Ridenour, Missy McKean-Matthews, Sandra Garces, Gregory Cameron
| DOI https://doi.org/10.25251/skin.1.supp.11

Page s12

Poster PDF

Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study)

Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Joana Goncalves, Eugenia Levi, Kristin Callis Duffin, Bruce Strober
| DOI https://doi.org/10.25251/skin.1.supp.12

Page s13

Poster PDF

Evaluation of the PGAxBSA Composite Tool in Patients with Moderate-to-Severe Plaque Psoriasis

Kristina Callis Duffin, J Mark Jackson, Joana Goncalves, Eugenia Levi, Jerry Bagel
| DOI https://doi.org/10.25251/skin.1.supp.13

Page s14

Poster PDF

First "Real-World" Insights on Apremilast Treatment for Patients with Plaque Psoriasis from the LAPIS-PSO Study: An Interim Analysis

Kristian Reich, Stefanie Bomas, Bernhard Korge, Maria Manasterski, Uwe Schwitchtenberg, Hannah Mentz, Kathrin Groegel
| DOI https://doi.org/10.25251/skin.1.supp.14

Page s15

Poster PDF

Group Concept Mapping to Understand the Patient Perspective and Burden of Psoriasis

Colby Evans, Louise Humphrey, Corey Pelletier, Stacie Hudgens
| DOI https://doi.org/10.25251/skin.1.supp.15

Page s16

Poster PDF

Improvements in Lesional Pain and Itch Symptoms with Brodalumab in Psoriasis Studies

Lawrence F Eichenfield, April Armstrong, Lawrence Green, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel
| DOI https://doi.org/10.25251/skin.1.supp.16

Page s17

Poster PDF

Incidence of Inflammatory Bowel Disease Events in Adalimumab Clinical Trials Across Indications

Jeffrey R Curtis, Dirk Elewaut, Su Chen, Maja Hojnik, Navit Naveh, Jaclyn K Anderson
| DOI https://doi.org/10.25251/skin.1.supp.17

Page s18

Poster PDF

Innovation in Topical Therapy for Psoriasis with Corticostereoid and Vitamin D Analogue Commbination

Siegfried Segaert, Neal Shear, Andrea Chiricozzi, Diamant Thaci, Jose M Carrascosa, Helen Young, Vincent Descamps
| DOI https://doi.org/10.25251/skin.1.supp.18

Page s19

Poster PDF

Keratolytic Activity of a Novel Dimethicone Formulation (PB/LO-112) Compared to 10% Salicylic Acid Oil in Patients with Psoriasis Capitis

Arnd Jacobi, Anke Mayer, Zografia Anastasiadou, Matthias Augustin
| DOI https://doi.org/10.25251/skin.1.supp.19

Page s20

Poster PDF

Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from CRIB, a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study

Alexa B Kimball, Xavier Mariette, Bincy Abraham, Ann Flynn, Frauke Forger, Anna Molto, Rene Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Wang, Eliza Chakravarty
| DOI https://doi.org/10.25251/skin.1.supp.20

Page s21

Poster PDF

Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry

Diamant Thaci, Alan Menter, Jashin J Wu, Dilek Arikan, Hartmut Kupper, Mareike Bereswill, Wendell C Valdecantos
| DOI https://doi.org/10.25251/skin.1.supp.21

Page s22

Poster PDF

Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Kristian Reich, Andrew Blauvelt, Diamant Thaci, Craig Leonardi, Yves Poulin, Daniel Burge, Luke Peterson, Catherine Arendt, Alice B Gottlieb
| DOI https://doi.org/10.25251/skin.1.supp.22

Page s23

Poster PDF

Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Matthias Augustin, Jolanta Weglowska, Mark Lebwohl, Carle Paul, Vincent Piquet, Howard Sofen, Andrew Blauvelt, Daniel Burge, Luke Peterson, Janice Drew, Robert Rollen
| DOI https://doi.org/10.25251/skin.1.supp.23

Page s24

Poster PDF

Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies

Mark Lebwohl, Kim A Papp, Jashin J Wu, Andrew Blauvelt, Alan Menter, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel
| DOI https://doi.org/10.25251/skin.1.supp.24

Page s25

Poster PDF

Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study

Jennifer Soung, Lisa Tiu, Karen Veverka, Chih-Ho Hong
| DOI https://doi.org/10.25251/skin.1.supp.25

Page s26

Poster PDF

Permeation Analysis of Novel Steroid Vehicles to Deliver and Retain Steroid in Skin Layers Associated with Psoriasis

Leon Kircik, Franklin Okumu, Sateesh Kandavilli
| DOI https://doi.org/10.25251/skin.1.supp.26

Page s27

Poster PDF

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

Desiree van der Heijde, Masato Okada, Chin Lee, Catherine L Shuler, Suchitrita Rathmann, Chen-Yen Lin, Philip J Mease
| DOI https://doi.org/10.25251/skin.1.supp.27

Page s28

Poster PDF

A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

Andrew Blauvelt, Joseph F Fowler, Jr., Ellen Schuck, Julia Jauch, Heike Woehling, Craig L Leonardi
| DOI https://doi.org/10.25251/skin.1.supp.28

Page s29

Poster PDF

Results of Subject's Assessment of Behavior and Attitudes (SABA) Survey Toward Psoriasis and Treatments in the PSO-INSIGHTFUL Study

Douglas DiRuggiero, Chih-Ho Hong, Lisa Tiu, Scott Freeman
| DOI https://doi.org/10.25251/skin.1.supp.29

Page s30

Poster PDF

A Retrospective Cohort Study of Real-World Experience with Apremilast in Patients with Plaque Psoriasis

April Armstrong, Eugenia Levi
| DOI https://doi.org/10.25251/skin.1.supp.30

Page s31

Poster PDF

Safety and Efficacy of Apremilast Through 104 Weeks in Patients swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study

Kristian Reich, Mark Goodfield, Lawrence Green, Kristine Nograles, Eugenia Levi, Richard GB Langley
| DOI https://doi.org/10.25251/skin.1.supp.31

Page s32

Poster PDF

XP-23829, a Novel Fumaric Acid Ester, is Efficacious in Reducing Psoriatic Lesions: Results from a Phase 2 Randomized Controlled Study

Alice B Gottlieb, Caitriona Ryan, Richard Kim, Aftab Alam, Sagar Munjal, Leon Kircik
| DOI https://doi.org/10.25251/skin.1.supp.32

Page s33

Poster PDF

Rosacea

Achieving an Endpoint of Completely Clear of Inflammatory Lesions and Erythema After Treatment of Rosacea Provides Multiple Positive Patient Outcomes: A Pooled Analysis

Guy Webster, Martin Schaller, Jerry Tan, Mark Jackson, Nabil Kerrouche, Gregor Schafer
| DOI https://doi.org/10.25251/skin.1.supp.57

Page s58

Poster PDF

The Anti-Inflammatory Properties of Ivermectin and Brimonidine in the Treatment of Papulopustular Rosacea

Linda Stein Gold, Edward Lain, Alison Harvey
| DOI https://doi.org/10.25251/skin.1.supp.58

Page s59

Poster PDF

Concurrent Administration of Ivermectin 1% Cream with Brimonidine 0.33% Gel Improves Efficacy and Tolerability in the Treatment of Moderate-to-Severe Rosacea

Linda Stein Gold, Kim Papp, Charles Lynde, Edward Lain, Melinda Gooderham, Sandra Johnson, Nabil Kerrouche, Gregor Schafer
| DOI https://doi.org/10.25251/skin.1.supp.59

Page s60

Poster PDF

Consistent Efficacy and Safety in Four Double-Blind, Vehicle-Controlled Studies of Ivermectin 1% Cream in the Treatment of Moderate-to-Severe Papulopustular Rosacea

Linda Stein Gold, JP York, Jean Jacovella
| DOI https://doi.org/10.25251/skin.1.supp.60

Page s61

Poster PDF

Evaluation of the Safety and Efficacy of Ultherapy for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea

Rosalyn George, Joel Schlessinger, Mark Lupin, David Amato, David McDaniel
| DOI https://doi.org/10.25251/skin.1.supp.61

Page s62

Poster PDF

Topical Minocycline Foam (FMX-103) for the Treatment of Moderate-to-Severe Rosacea: Results of a Phase 2, Randomized, Double-Blind, Multicenter Clinical Study

Ulrich Mrowietz, Tal Hetzroni Kedem, Rita Kenyan, Meir Eini, Dov Tamarkin, Mitchell Shirvan
| DOI https://doi.org/10.25251/skin.1.supp.62

Page s63

Poster PDF

Cosmetic

Clinical Efficacy and Tolerability of a Cosmetic Growth Factor Serum for Overall Facial Photodamage

Elizabeth Makino, Priscilla Tan, Rahul C Mehta
| DOI https://doi.org/10.25251/skin.1.supp.63

Page s64

Poster PDF

A Comprehensive Analysis of the Safety of a New Range of Injectable Hyaluronic Acid Products for Aesthetic Indications

David Bank, Derek H Jones, Cindy Wong, J H Mashburn
| DOI https://doi.org/10.25251/skin.1.supp.64

Page s65

Poster PDF

Differential Facial Aesthetic Treatment Considerations for Skin of Color Populations: African American, Asian, and Hispanic

Charles Boyd, Annie Chiu, Jose R Montes, Vic Narurkar, Garrett T Shumate, Conor J Gallagher
| DOI https://doi.org/10.25251/skin.1.supp.65

Page s66

Poster PDF

DFD-01, a Betamethasone Dipropionate 0.05% Spray Lotion. Reduces Transepidermal Water Loss and Improves Skin Hydration and Elasticity

J Mark Jackson, Gary L Grove, Kent Allenby, Tim Houser
| DOI https://doi.org/10.25251/skin.1.supp.66

Page s67

Poster PDF

Efficacy and Consumer Perception of a 96% Natural Cream Containing Lime Pearl Extract and Willow Bark Extract when Used by Subjects with Clinically Determined Keratosis Pilaris

A Donald, R Rozanski
| DOI https://doi.org/10.25251/skin.1.supp.67

Page s68

Poster PDF

An Effective yet Gentle Foaming Facial Cleanser Specifically Designed for Redness-Prone Skin

Matthew H Meckfessel, Sandrine Teissedre, Nadege Lachmann, Francince Santoro
| DOI https://doi.org/10.25251/skin.1.supp.68

Page s69

Poster PDF

Efficacy of IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines in Male Subjects: Post-Hoc Analyses from Randomized. Double-Blind Pivotal Studies

Derek H Jones, Martina Kerscher, Thorin Geister, Michael A Hast, Petra Weissenberger
| DOI https://doi.org/10.25251/skin.1.supp.69

Page s70

Poster PDF

Efficacy of an Ointment Body Spray to Improve the Appearance of Dry, Ashy Skin and Alleviate Moderate to Severe Dryness on the Heel

T M Weber, C E Arrowitz, L I Jiang, K Qian, A Filbry
| DOI https://doi.org/10.25251/skin.1.supp.70

Page s71

Poster PDF

Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate-to-Severe Forehead Lines

Steve Fagien, Joel Cohen, William Coleman, Gary Monheit, Jean Caruthers, Cheri Mao, Domenico Vitarella, Xiaofang Lei, Bhushan Hardas
| DOI https://doi.org/10.25251/skin.1.supp.71

Page s72

Poster PDF

Efficacy and Safety of OnabotulinumtoxinA for Moderate-to-Severe Forehead Lines in Subjects with Upper Facial Lines

Koen De Boulle, Philip Werschler, Michael H Gold, Gerhard Sattler, Patricia Ogilvie, Cheri Mao, Domenico Vitarella, Xiaofang Lei, Bhushan Hardas
| DOI https://doi.org/10.25251/skin.1.supp.72

Page s73

Poster PDF

Evaluation of the Efficacy and Tolerability of a Topical Facial Serum in Improving Signs of Aging

Richard L Gallo, Susana Raab, Margarita Yatskayer, Stephen Lynch
| DOI https://doi.org/10.25251/skin.1.supp.73

Page s74

Poster PDF

How to Treat Dryness, Hyperkeratosis, and Cracks of Diabetic Patients' Feet

D Moyal, S Seite
| DOI https://doi.org/10.25251/skin.1.supp.74

Page s75

Poster PDF

Immediate and Long-Term Efficacy of a Two-Step Topical Hyaluronic Acid Lip Treatment

Elizabeth T Makino, Priscilla Tan, Rahul Mehta
| DOI https://doi.org/10.25251/skin.1.supp.75

Page s76

Poster PDF

Juvederm Vollure XC is Safe and Effective for Correcting Nasolabial Folds: Results from a Randomized Controlled Study

Gary Monheit, Pearl E Grimes, Bhushan Hardas, Vince Lin, Diane K Murphy
| DOI https://doi.org/10.25251/skin.1.supp.76

Page s77

Poster PDF

Juvederm Vollure XC is Safe and Effective for Long-Term Correction of Nasolabial Folds: Results from a Multicenter, Randomized, Controlled Study

Steven Dayan, Corey S Maas, Pearl E Grimes, Kenneth Beer, Gary Monheit, Bhushan Hardas, Vince Lin
| DOI https://doi.org/10.25251/skin.1.supp.77

Page s78

Poster PDF

Lip and Perioral Enhancement with HA Dermal Fillers in Individuals with Fitzpatrick Skin Types IV-VI

Susan C Taylor, Jeanine B Downie, Ava Shamban, Julius Few, Bashir Khan, Andrew Schumacher, Conor Gallagher
| DOI https://doi.org/10.25251/skin.1.supp.78

Page s79

Poster PDF

Maximizing Pan-Facial Aesthetic Outcomes; Findings and Recommendations from the HARMONY Study

Michael Kaminer, Joel L Cohen, Vic Narurkar, Ava Shamban, Phil Werschler, Garrett T Shumate, Conor J Gallagher
| DOI https://doi.org/10.25251/skin.1.supp.79

Page s80

Poster PDF

An Observational Study of the Safety and Efficacy of Tissue Stabilized-Guided Subcision to Improve the Appearance of Cellulite

Roy G Geronemus, Jeremy A Brauer, Suzanne L Kilmer, Simeon H Wall, Jr., Jeremy B Green, Joel L Cohen, Robert A Weiss, Tina S Alster, Michael S Kaminer
| DOI https://doi.org/10.25251/skin.1.supp.80

Page s81

Poster PDF

OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

Steven Dayan, Patricia Ogilvie, Alexander Z Rivkin, Steven G Yoelin, Julie K Garcia, Ilia L Ferrusi
| DOI https://doi.org/10.25251/skin.1.supp.81

Page s82

Poster PDF

An Open Label, Prospective, Clinical Study to Evaluatee the Anti-aging Effects and the Safety of a Novel Ccosmetic Facial Day Cream

C Granger, G Martinez-Masana, A Garre
| DOI https://doi.org/10.25251/skin.1.supp.82

Page s83

Poster PDF

Pan-facial Treatment Positively and Significantly Impacts Social Perception

Steven Dayan, Alexander Rivkin, Jonathan M Sykes, Craig F Teller, Susan H Weinkle, Garrett T Shumate, Conor J Gallagher
| DOI https://doi.org/10.25251/skin.1.supp.83

Page s84

Poster PDF

Performance of a Facial Night Moisturizer for Redness-Prone Skin

Matthew H Meckfessel, Sandrine Teissedre, Nadege Lachmann, Francince Santoro
| DOI https://doi.org/10.25251/skin.1.supp.84

Page s85

Poster PDF

The Psychological Impacts of Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies

Steven Dayan, Steven G Yoelin, Koenraad De Boulle, Ilia L Ferrusi
| DOI https://doi.org/10.25251/skin.1.supp.85

Page s86

Poster PDF

Reduction of Facial Redness with Resveratrol Added to Topical Product Containing Green Tea Polyphenols and Caffeine

Sarah Y Siu, Georgina M Ferzli, Neil Brody
| DOI https://doi.org/10.25251/skin.1.supp.86

Page s87

Poster PDF

Simultaneous Treatment of Moderate-to-Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines wtih OnabotulinumtoxinA from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

Steven Dayan, Patricia Ogilvie, Alexander Z Rivkin, Steven G Yoelin, Julie Garcia, Ilia L Ferrusi
| DOI https://doi.org/10.25251/skin.1.supp.87

Page s88

Poster PDF

A Split-Face Design Clinical Trial to Evaluate the Efficacy of a Masque when Used Post-Full Face Fraxel® Laser Treatment

Ana Du, Susana Raab, Margarita Yatskayer, Stephen Lynch
| DOI https://doi.org/10.25251/skin.1.supp.88

Page s89

Poster PDF

Tolerability and Efficacy of a Moisturizing Broad Spectrum Sunscreen Formulated for Redness-Prone Skin

Matthew H Meckfessel, Sandrine Teissedre, Nadege Lachmann, Francine Santoro
| DOI https://doi.org/10.25251/skin.1.supp.89

Page s90

Poster PDF

Two On-Label Injection Volumes of AbobotulinumtoxinA (ABO) Produce Simlar Safety and Efficacy Results when Used to Treate Moderate to Sever Glabellar Lines

Joely Kaufman, Joel Cohen, Marina Peredo, Brandie Jonas, Alessandra Nogueira, Jay H Mashburn
| DOI https://doi.org/10.25251/skin.1.supp.90

Page s91

Poster PDF

VYC-17.5L is Effective for the Treatment of Static and Dynamic Radial Cheek Lines: Results from the BEAM Study

Patricia Ogilvie, Bernhard Fink, Christopher Leys, Sylvia Lipko-Godlewska, Francois Niforos, Graeme Kerson, Michael Silberberg
| DOI https://doi.org/10.25251/skin.1.supp.91

Page s92

Poster PDF

Nail Unit Disorders

Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Alice B Gottlieb, Boni E Elewski, Martin M Okun, Jerry Bagel, Yves Poulin, Yihua Gu, Ziqian Geng, David A Williams, Wendell C Valdecantos
| DOI https://doi.org/10.25251/skin.1.supp.96

Page s97

Poster PDF

Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis

Chris Adigun, Tracey C Vlahovic, Michael B McClellan, Kailas D Thakker, Ryan R Klein, Tuan A Elstrom, Daniel B Ward, Jr.
| DOI https://doi.org/10.25251/skin.1.supp.97

Page s98

Poster PDF

Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials

Mark G Lebwohl, Lawrence Green, Sylvia Hsu, Shipra Rastogi, Tina Lin, Radhakrishnan Pillai, Robert J Israel
| DOI https://doi.org/10.25251/skin.1.supp.98

Page s99

Poster PDF

Melanoma

31-Gene Expression Profile Assessing Metastatic Risk in Melanoma Patients: Issues Impacting Patient Selection

Ryan M Svoboda, Alex M Glazer, Darrell S Rigel
| DOI https://doi.org/10.25251/skin.1.supp.104

Page s105

Poster PDF

Clinical Reliability and Reproducibility of a Prognostic 31-Gene Expression Profile Test for Cutaneous Melanoma, and Association of the Test with Standard Clinicopathologic Factors

Robert W Cook, Kristen Oelschlager, Trisha Poteet, Derek Maetzold, John Stone, Federico Monzon
| DOI https://doi.org/10.25251/skin.1.supp.105

Page s106

Poster PDF

Clinical Impact of a 31-Gene Expression Profile Test on Physician Recommendations for Management of Melanoma Patients in a Prospectively Tested Cohort

Martin Fleming, Clare Johnson, Kyle Covington, Joseph Gadzia, Larry Dillon, Frederico Monzon
| DOI https://doi.org/10.25251/skin.1.supp.106

Page s107

Poster PDF

Comparing Electrical Impedance Spectroscopy to Traditional Clinical Adjunctive Tools in the Detection of Melanoma

Ryan M Svoboda, Abigail I Franco, Darrell S Rigel
| DOI https://doi.org/10.25251/skin.1.supp.107

Page s108

Poster PDF

Health Econommic Implications of a Non-Invasive Gene Expression Test for Primary Cutaneous Melanoma

John Hornberger, Darrell Rigel
| DOI https://doi.org/10.25251/skin.1.supp.108

Page s109

Poster PDF

Interim Analysis of Survival Outcomes in a Prospective Multicenter Cohort Evaluating a Prognostic 31-Gene Expression Profile (GEP) Test for Melanoma

Eddy C Hsueh, James R DeBloom, Jonathan Lee, Jeffrey J Sussman, Craig L Slingluff, Jr, Kelly M McMasters
| DOI https://doi.org/10.25251/skin.1.supp.109

Page s110

Poster PDF

Non-Melanoma Skin Cancers and Benign Cutaneous Tumors

An Adhesive Patch Biopsy Based Gene Expression Test to Non-invasively Differentiate Basal Cell and Squamous Cell Carcinomas from Actinic Keratoses and Other Skin Lesions of Similar Appearance

James Sligh, Zuxu Yao, Burkhard Jansen
| DOI https://doi.org/10.25251/skin.1.supp.110

Page s111

Poster PDF

BF-200 ALA for the Photodynamic Treatment of Non-Aggressive Basal Cell Carcinoma: Results of a Phase III Comparator Trial

C A Morton, R M Szeimies, R Dominicus, T Dirschka, S Ibbotoson, B Schmitz, H Lubbert
| DOI https://doi.org/10.25251/skin.1.supp.111

Page s112

Poster PDF

Characterization of BF-200 ALA: A Nanoemulsion-Based Drug Delivery System for ALA-PDT

L Schmitz, T Maisch, M Fouget, B Novak, A K Hoeh, T Dirschka, H Lubbert
| DOI https://doi.org/10.25251/skin.1.supp.112

Page s113

Poster PDF

Comparison of Electronic Brachytherapy and Mohs Micrographic Surgery for the Treatment of Early-Stage Non-Melanoma Skin Cancer: A Matched Pair Cohort Study

Rakesh Patel, Robert Strimling, Stephen Doggett, Mark Willoughby, Erick Mafong, Kenneth Miller, Lawrence Dardick
| DOI https://doi.org/10.25251/skin.1.supp.113

Page s114

Poster PDF

Daylight Photodynamic Therapy of Actinic Keratosis with BF-200 ALA compared to MAL

T Dirschka, S Ekanayake-Bohlig, R Dominicus, R Aschoff, E Herrera-Ceballos, R Botella-Estrada, A Hunfeld, B Schmitz, H Lubbert, S Puig
| DOI https://doi.org/10.25251/skin.1.supp.114

Page s115

Poster PDF

Photodynamic Therapy for Actinic Keratosis and Field Cancerization Using BF-200 ALA: Results of Pivotal Phase III Trials and Follow-Up

T Dirschka, U Reinhold, M Foguet, B Novak, B Schmitz, H Luebbert, R M Szeimies
| DOI https://doi.org/10.25251/skin.1.supp.116

Page s117

Poster PDF

Prevention of Actinic Keratosis by a Very High UVB/UVA Daily Photoprotectant

S Seite, D Moyal
| DOI https://doi.org/10.25251/skin.1.supp.117

Page s118

Poster PDF

Safety and Efficacy of A-101 Hydrogen Peroxide Topical Solution in Adults with Seborrheic Keratosis: Results from the Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study

Zoe D Draelos, Steven E Kempers, Stacy R Smith, David C Wilson, Christopher V Powala, Mark Bradshaw, Esther Estes, Stuart D Shanler
| DOI https://doi.org/10.25251/skin.1.supp.118

Page s119

Poster PDF

Sonidegib Efficacy and Safety in Patients with Locally Advanced Basal Cell Carcinoma Based on Tumor Aaggressiveness

Michael R Migden, Reinhard Dummer
| DOI https://doi.org/10.25251/skin.1.supp.119

Page s120

Poster PDF

Triple Hedgehog Pathway Inhibition for Treatment of Basal Cell Carcinoma

Xinyi Yang, Matthew S Dinehart
| DOI https://doi.org/10.25251/skin.1.supp.120

Page s121

Poster PDF

Dermatologic Surgery and Wound Healing

Low Rate of Keloid Recurrences Following Treatment of Keloidectomy Sites with a Biological Effective Dose 30 of Superficial Radiation

Brian Berman, Mark S Nestor, Joshua Fox, Michael Jones, George Schmieder, Eduardo T Weiss
| DOI https://doi.org/10.25251/skin.1.supp.121

Page s122

Poster PDF

Observer-Blinded, Randomized Study to Determine the Safety and Efficacy of a Silicone Gel versus a Gel Containing Onion Extract for the Appearance and Symptoms of Surgical Scars

Brian Berman, Mark Nestor
| DOI https://doi.org/10.25251/skin.1.supp.122

Page s123

Poster PDF

Pilot Study Assessing the Efficacy of a Novel Topical Adhesive for Dermatologic Excisional Wound Closure

Ryan M Svoboda, Joshua D Zuckerman, Darrell S Rigel
| DOI https://doi.org/10.25251/skin.1.supp.123

Page s124

Poster PDF

Urticaria

Design and rational of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)

Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Gretty Deutsch, Frederica DeTakacsy, Lenka Rihakova
| DOI https://doi.org/10.25251/skin.1.supp.124

Page s125

Poster PDF

Efficacy and Safety of Omalizumab in Japanese and Korean Patients with Chronic Idopathic/Spontaneous Urticaria (CIU/CSU: Results from the Phase 3 POLARIS Study

Michihiro Hide, Hae-Sim Park, Atsuyuki Igarashi, Young-Min Ye, Tae-Bum Kim, Akiko Yagami
| DOI https://doi.org/10.25251/skin.1.supp.125

Page s126

Poster PDF

Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study

Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Antonio Vieira, Frederica De Takacsy, Lenka Rihakova
| DOI https://doi.org/10.25251/skin.1.supp.126

Page s127

Poster PDF

Hidradenitis Suppurativa

Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)

Christos C Zouboulis, Martin M Okun, Robert Gniadecki, Peter A Foley, Charles Lynde, Jamie Weisman, Piyalal Karunaratne, David A Williams
| DOI https://doi.org/10.25251/skin.1.supp.127

Page s128

Poster PDF

Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial

| DOI https://doi.org/10.25251/skin.1.supp.128

Page s129

Poster PDF

Impact of Baseline Smoking Status and Body Mass Index in Patients with Hidradenitis Suppurativa Treated with Adalimumab or Placebo in Phase 2 or 3 Studies

Amit Garg, Hessel H van der Zee, Ziqian Geng, Gerit D Mulder
| DOI https://doi.org/10.25251/skin.1.supp.129

Page s130

Poster PDF

Pediculosis

Abametapir Lotion, 0.74% Demonstrates High Elimination Rates of Head Lice with a Single Application in Phase 3 Trials

Lydie Hazan, Robert S Haber, Robert S Haber, Michael Husseman, Michael Husseman, Katie Shepherd, Katie Shepherd, Sharon Hanegraaf, Sharon Hanegraaf, Tina Ahveninen, Tina Ahveninen, Lisa Jenkins, Lisa Jenkins, Hugh Alsop, Hugh Alsop, Vernon M Bowles, Vernon M Bowles
| DOI https://doi.org/10.25251/skin.1.supp.130

Page s131

Poster PDF

Abametapir Lotion, 0.74%, a Novel Therapy for the Treatment of Head Lice, Pooled Safety Results from 11 Trials, in Children as Young as 6 Months

Lydie Hazan, David Cardona, Sharon Hanegraaf, Tina Ahveninen, Hugh Alsop, Vernon M Bowles
| DOI https://doi.org/10.25251/skin.1.supp.131

Page s132

Poster PDF

A Randomized Double-Blind, Vehicle-Controlled Study of the Ovicidal Efficacy of a New Head Lice Therapy, Abametapir Lotion, 0.74%, Administered for the Treatment of Head Lice Infestation

Scott Arnold, Sharon Hanegraaf, Tina Ahvenien, Hugh Alsop, Vernon M Bowles
| DOI https://doi.org/10.25251/skin.1.supp.132

Page s133

Poster PDF